208 related articles for article (PubMed ID: 32300639)
21. Cellular reservoirs of latent cytomegaloviruses.
Reddehase MJ; Lemmermann NAW
Med Microbiol Immunol; 2019 Aug; 208(3-4):391-403. PubMed ID: 31011793
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic herpes simplex virus and immunotherapy.
Ma W; He H; Wang H
BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
[TBL] [Abstract][Full Text] [Related]
23. Ad5
Uusi-Kerttula H; Davies JA; Thompson JM; Wongthida P; Evgin L; Shim KG; Bradshaw A; Baker AT; Rizkallah PJ; Jones R; Hanna L; Hudson E; Vile RG; Chester JD; Parker AL
Clin Cancer Res; 2018 Sep; 24(17):4215-4224. PubMed ID: 29798908
[No Abstract] [Full Text] [Related]
24. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
25. Poxvirus oncolytic virotherapy.
Torres-Domínguez LE; McFadden G
Expert Opin Biol Ther; 2019 Jun; 19(6):561-573. PubMed ID: 30919708
[TBL] [Abstract][Full Text] [Related]
26. Herpes Simplex Virus 1 Infection Promotes the Growth of a Subpopulation of Tumor Cells in Three-Dimensional Uveal Melanoma Cultures.
Valyi-Nagy T; Fredericks B; Ravindra A; Hopkins J; Shukla D; Valyi-Nagy K
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045986
[TBL] [Abstract][Full Text] [Related]
27. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
[TBL] [Abstract][Full Text] [Related]
28. Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation.
Neuber S; Wagner K; Goldner T; Lischka P; Steinbrueck L; Messerle M; Borst EM
J Virol; 2017 Jun; 91(12):. PubMed ID: 28356534
[TBL] [Abstract][Full Text] [Related]
29. Rhesus CMV: an emerging animal model for human CMV.
Powers C; Früh K
Med Microbiol Immunol; 2008 Jun; 197(2):109-15. PubMed ID: 18193454
[TBL] [Abstract][Full Text] [Related]
30. Modeling Human Cytomegalovirus in Humanized Mice for Vaccine Testing.
Koenig J; Theobald SJ; Stripecke R
Vaccines (Basel); 2020 Feb; 8(1):. PubMed ID: 32079250
[TBL] [Abstract][Full Text] [Related]
31. Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions.
Kim J; Hall RR; Lesniak MS; Ahmed AU
Viruses; 2015 Nov; 7(12):6200-17. PubMed ID: 26633462
[TBL] [Abstract][Full Text] [Related]
32. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
[TBL] [Abstract][Full Text] [Related]
33. Expression of Human Cytomegalovirus IE1 Leads to Accumulation of Mono-SUMOylated PML That Is Protected from Degradation by Herpes Simplex Virus 1 ICP0.
Hou W; Cruz-Cosme R; Wen F; Ahn JH; Reeves I; Luo MH; Tang Q
J Virol; 2018 Dec; 92(23):. PubMed ID: 30258013
[TBL] [Abstract][Full Text] [Related]
34. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH
Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
[TBL] [Abstract][Full Text] [Related]
36. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells.
Li Y; Li YF; Si CZ; Zhu YH; Jin Y; Zhu TT; Liu MY; Liu GY
Virus Res; 2016 Jul; 220():172-8. PubMed ID: 27157859
[TBL] [Abstract][Full Text] [Related]
37. Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors.
Kiener R; Fleischmann M; Wiegand MA; Lemmermann NAW; Schwegler C; Kaufmann C; Renzaho A; Thomas S; Felder E; Niller HH; Asbach B; Wagner R
J Virol; 2018 Aug; 92(15):. PubMed ID: 29769344
[TBL] [Abstract][Full Text] [Related]
38. Human Cytomegalovirus Particles Treated with Specific Antibodies Induce Intrinsic and Adaptive but Not Innate Immune Responses.
Wu Z; Qin R; Wang L; Bosso M; Scherer M; Stamminger T; Hotter D; Mertens T; Frascaroli G
J Virol; 2017 Nov; 91(22):. PubMed ID: 28878085
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
[TBL] [Abstract][Full Text] [Related]
40. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
